CL2020001850A1 - Vectores inmunoevasivos y uso para terapia génica. - Google Patents

Vectores inmunoevasivos y uso para terapia génica.

Info

Publication number
CL2020001850A1
CL2020001850A1 CL2020001850A CL2020001850A CL2020001850A1 CL 2020001850 A1 CL2020001850 A1 CL 2020001850A1 CL 2020001850 A CL2020001850 A CL 2020001850A CL 2020001850 A CL2020001850 A CL 2020001850A CL 2020001850 A1 CL2020001850 A1 CL 2020001850A1
Authority
CL
Chile
Prior art keywords
immunoevasive
vectors
gene therapy
envelope
viral particle
Prior art date
Application number
CL2020001850A
Other languages
English (en)
Inventor
Genine Winslow
Original Assignee
Chameleon Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chameleon Biosciences Inc filed Critical Chameleon Biosciences Inc
Publication of CL2020001850A1 publication Critical patent/CL2020001850A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00051—Methods of production or purification of viral material
    • C12N2750/00052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporciona un vector viral envuelto que comprende una partícula viral circundada por una envoltura, en donde la partícula viral comprende un transgén heterólogo y la envoltura comprende una bicapa lipídica y una o más moléculas inmunosupresoras y métodos para preparar y usar las mismas.
CL2020001850A 2018-01-11 2020-07-10 Vectores inmunoevasivos y uso para terapia génica. CL2020001850A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862616167P 2018-01-11 2018-01-11
US201862768779P 2018-11-16 2018-11-16

Publications (1)

Publication Number Publication Date
CL2020001850A1 true CL2020001850A1 (es) 2020-12-04

Family

ID=65444323

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001850A CL2020001850A1 (es) 2018-01-11 2020-07-10 Vectores inmunoevasivos y uso para terapia génica.

Country Status (14)

Country Link
US (1) US20200338216A1 (es)
EP (1) EP3737768A1 (es)
JP (2) JP7406253B2 (es)
KR (1) KR20200128519A (es)
CN (1) CN111836896A (es)
AU (1) AU2019206639A1 (es)
BR (1) BR112020014093A2 (es)
CA (1) CA3088897A1 (es)
CL (1) CL2020001850A1 (es)
IL (1) IL275951A (es)
MX (1) MX2020007390A (es)
RU (1) RU2020126574A (es)
SG (1) SG11202006298XA (es)
WO (1) WO2019140311A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021180118A1 (en) * 2020-03-11 2021-09-16 Shanghai Belief-Delivery Biomed Co., Ltd. Novel use of aspirin compound in increasing nucleic acid expression
BR112022026309A2 (pt) * 2020-06-24 2023-01-17 Chameleon Biosciences Inc Vesículas extracelulares com moduladores imune
CN112410304A (zh) * 2020-11-12 2021-02-26 天津大学 一种基因修饰的外泌体及其制备方法和应用
WO2023028035A1 (en) * 2021-08-23 2023-03-02 University Of Florida Research Foundation, Incorporated Lipid enveloped recombinant aav particles for gene therapy use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001512142A (ja) * 1997-07-31 2001-08-21 カイロン コーポレイション 宿主の免疫抑制を介するａａｖベクターの再投与を可能にする方法
JP2002514388A (ja) * 1998-04-29 2002-05-21 ユニバーシティー・オブ・サウザーン・カリフォルニア 修飾エンベロープエスコート蛋白質を含むレトロウイルスベクター
DE19827457C1 (de) * 1998-06-19 2000-03-02 Medigene Ag Strukturprotein von AAV, seine Herstellung und Verwendung
WO2006007539A1 (en) * 2004-07-01 2006-01-19 Virxsys Corporation Vector packaging cell line
CA2612355A1 (en) * 2005-06-16 2006-12-28 Virxsys Corporation Antibody complexes
JP4691611B1 (ja) 2010-01-15 2011-06-01 富士フイルム株式会社 有機電界発光素子
WO2011106376A2 (en) * 2010-02-23 2011-09-01 The General Hospital Corporation Use of microvesicles in the treatment of medical conditions
CN106714826A (zh) * 2014-09-07 2017-05-24 西莱克塔生物科技公司 用于减弱基因表达调节抗病毒转移载体免疫应答的方法和组合物
CN104887717B (zh) * 2015-06-04 2019-05-31 爱康得生物医学技术（苏州）有限公司 一种免疫增强试剂
US20190038778A1 (en) * 2016-02-05 2019-02-07 The General Hospital Corporation Hybrid System for Efficient Gene Delivery to Cells of the Inner Ear

Also Published As

Publication number Publication date
EP3737768A1 (en) 2020-11-18
CN111836896A (zh) 2020-10-27
WO2019140311A1 (en) 2019-07-18
BR112020014093A2 (pt) 2020-12-01
RU2020126574A (ru) 2022-02-11
US20200338216A1 (en) 2020-10-29
JP2023160938A (ja) 2023-11-02
AU2019206639A1 (en) 2020-08-20
SG11202006298XA (en) 2020-07-29
KR20200128519A (ko) 2020-11-13
JP7406253B2 (ja) 2023-12-27
CA3088897A1 (en) 2019-07-18
IL275951A (en) 2020-08-31
MX2020007390A (es) 2020-10-14
JP2021510522A (ja) 2021-04-30

Similar Documents

Publication Publication Date Title
CL2020001850A1 (es) Vectores inmunoevasivos y uso para terapia génica.
CL2017002731A1 (es) Adenovirus oncolítico que codifica una proteína b7
CL2019000167A1 (es) Novedosas proteínas de la cápside del virus adenoasociado.
AR122050A2 (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
CO2019000395A2 (es) Genes de mini–distrofina optimizados y casetes de expresión y su uso
CL2023000264A1 (es) Nuevos vectores virales adeno-asociados dirigidos al hígado
CO2021017741A2 (es) Proteínas de fusión flt3l-fc y métodos de uso
CO2021006362A2 (es) Construcciones de ácido nucleico y métodos de uso
CL2017001584A1 (es) Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso
BR112018013930A2 (pt) vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus
CO2020006900A2 (es) Medios y método para preparar vectores virales y usos de los mismos
CO2021006301A2 (es) Composiciones y métodos de inmunoterapia
ECSP17059343A (es) ARNi VARIANTE
CL2020002809A1 (es) Construcciones para terapia génica y métodos para su uso
CO2020012584A2 (es) Suministro intracelular de biomoléculas para modificar respuestas inmunes
CL2021001466A1 (es) Sistemas activos dinámicos acromosómicos.
CR20190397A (es) Método para producir anticuerpos multiespecíficos
DOP2016000220A (es) PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS.
CL2021001034A1 (es) Métodos y composiciones para terapia con células oculares
AR104604A1 (es) ANTICUERPOS ANTI-FcRn
PE20211660A1 (es) Neoantigenos prostaticos y sus usos
AR113450A1 (es) Vectores adenovirales competentes en la replicación
CO2021007320A2 (es) Sistemas de edición génica para editar un gen regulador de la conductancia transmembrana de la fibrosis quística (cftr)
CO2021016797A2 (es) Composiciones de virus adenoasociadas para la transferencia del gen arsa y métodos de uso de las mismas
CL2018002900A1 (es) Construcciones de adn para la fabricación de polipéptidos bioterapéuticos para su uso en vacunas animales y agentes terapéuticos.